MB Pharma

What MB Pharma does

MB Pharma Group s.r.o. is a Czech privately-held biotechnology and pharmaceutical company headquartered in Prague, with an R&D laboratory at INMEC in Brno-Medlanky. Founded as a GMP-certified manufacturer under SÚKL oversight since 2016, the company focuses on microbiological research, development, and manufacturing across three core technology pillars: bacteriophages (bacterial viruses that selectively infect target bacteria), bacterial lysates (heat-inactivated bacterial cultures used for non-specific immune activation), and bacterial enzymes (microbial metabolites including collagenase). The company has built a vertically integrated contract research and GMP manufacturing services business, alongside a proprietary product pipeline centered on antibiotic-resistance alternatives.

The company's commercial product portfolio spans two clinical-stage bacteriophage therapeutics and two specialty products. DUOFAG® is a Phase IIB bacteriophage therapeutic targeting surgical wound infections caused by Staphylococcus aureus and Pseudomonas aeruginosa, while TRIOFAG® is in Phase I targeting respiratory tract infections caused by Acinetobacter baumannii, Klebsiella pneumoniae, and S. aureus. LYZODOL is a bacterial-lysate dietary supplement sold via a partnership with FAGOFARMA's e-commerce platform (fagocare.cz), and Collagenase MB is a Clostridium histolyticum-derived enzyme used for Langerhans islet isolation in diabetes transplantation workflows. Revenue is generated through B2B contract research, GMP manufacturing, aseptic filling (Class A-D cleanrooms), and direct product sales targeting pharmaceutical companies, transplant centers, and via FAGOFARMA for consumer supplements.

Operated as a B2B sales-led organization, MB Pharma is primarily funded through non-dilutive public grants from Czech and EU sources including the Ministry of Industry and Trade (MPO), the Technology Agency of the Czech Republic (TAČR), EU structural funds, and the European Defence Fund (RESILIENCE-R-2023 project). The company holds research collaborations with Masaryk University, the Institute of Biotechnology of the Czech Academy of Sciences, and the Veterinary Faculty of Brno. Strategic research priorities include combined phage-antibiotic therapy, COVID-19 vaccine development, CBRN medical countermeasures, and the AMBRA automated microbiological reaction system, with manufacturing capacity scaled from 20L to 150L batches through lyophilization innovation.

Name

MB Pharma

Legal name

MB Pharma Group s.r.o.

Website

https://mbph.cz

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

MB Pharma is a Czech GMP-certified biotech contract manufacturer and therapeutics developer specializing in bacteriophage-based therapies, bacterial lysates, and enzymes for antibiotic-resistant infections, serving pharma companies, transplant centers, and supplement consumers.

Ownership category

akta.pro rank

Product category

Biopharmaceutical contract manufacturing and bacteriophage therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)

akta.pro secondary industries

CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD), Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery) (HLAAAFAJ)

Keywords

• Bacteriophage therapeutics
• GMP manufacturing services
• Bacterial enzyme products
• Contract research microbiology
• Antibiotic resistance therapies

Headquarters

HQ city

Prague

HQ country

Czechia

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Contract Research and Development: Contract research services covering all stages of bacteriological preparation design and preparation including phage isolation, identification, cultivation process development, purification and analytical method design, and GMP transfer preparation.
2. GMP Manufacturing Services: GMP-certified manufacturing of bacterial enzymes, bacterial lysates, and bacteriophages including purification, quality control, and release of active pharmaceutical ingredients or medicinal products by qualified persons.
3. Aseptic Filling Services: Aseptic filling of sterile preparations in small volumes in Class A to D cleanrooms, including quality control, sterility testing, mediafill, and stability studies.
4. Product Sales - LYZODOL: Sale of LYZODOL dietary supplement through e-commerce partner FAGOFARMA (fagocare.cz). Product is sold in fast-dissolving tablet form with light menthol flavor.
5. Product Sales - Collagenase MB: Sale of Collagenase MB enzyme product for tissue digestion applications, particularly for Langerhans islet isolation for diabetes treatment.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

MB Pharma develops and manufactures microbiology, biotechnology, and pharmaceutical products with a core focus on bacteriophage-based therapeutics and bacterial enzymes. The company runs GMP-certified contract research, development, and manufacturing services for bacterial enzymes, lysates, and bacteriophages, complemented by proprietary products including clinical-stage bacteriophage therapies (DUOFAG®, TRIOFAG®), the LYZODOL bacterial lysate dietary supplement, and Collagenase MB enzyme for tissue digestion.

Product overview

MB Pharma is a Czech biotechnology company focused on research, development, and manufacturing in microbiology, biotechnology, and pharmacy. The company operates a contract research and GMP manufacturing services division alongside a portfolio of phage-based therapeutic products in clinical development. Core products include DUOFAG® and TRIOFAG® (phage-based therapeutics for wound and respiratory infections), LYZODOL (dietary supplement with bacterial lysates), and COLLAGENASE MB (enzyme preparation for tissue digestion). The company also manufactures bacterial lysates, bacteriophages, and bacterial enzymes, offering contract research, GMP production, aseptic filling, and related laboratory services.

Differentiator

Problem solved

Functional benefit

Brands

• LYZODOL: Revolutionary next-generation dietary supplement based on bacterial lysates for upper respiratory tract health support.
• Collagenase MB
• DUOFAG
• TRIOFAG

Products and services

• DUOFAG® Bacteriophage-based therapeutic product in clinical Phase IIB, designed for treating surgical wound infections caused by Staphylococcus aureus and Pseudomonas aeruginosa.
• TRIOFAG® Bacteriophage-based therapeutic product targeting respiratory tract infections caused by Acinetobacter baumannii, Klebsiella pneumoniae, and Staphylococcus aureus, currently in Phase I clinical development.
• LYZODOL Next-generation dietary supplement containing inactivated bacteria from four selected strains (Staphylococcus aureus, Klebsiella pneumoniae, Lelliottia amnigena, Cutibacterium acnes) for preventing upper respiratory tract infections, available as fast-dissolving tablets with menthol flavor.
• COLLAGENASE MB Collagenase preparation derived from Clostridium histolyticum bacteria, consisting of type I and II collagenases processed through dialysis, filtration, and ultrafiltration, suitable for digesting various organic tissues including Langerhans islet isolation for diabetes treatment.
• GMP Contract Research & Manufacturing Services Contract research, development, and GMP-compliant manufacturing of bacterial enzymes, bacterial lysates, and bacteriophages for pharmaceutical and biotechnology clients, including purification, quality control, and release of active substances and medicinal products by qualified persons.
• Aseptic Filling Service Aseptic filling of sterile preparations in small volumes in cleanroom class A to D, including quality control per specifications, sterility testing, mediafill, and stability studies.

Quantifiable outcome

• DUOFAG® has progressed to Phase IIB clinical trial following successful Phase I safety confirmation
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Masarykova univerzita (MU)coreStrategic or Co-development Partner · 1 January 2020Collaboration in combined phage therapy project for chronic respiratory diseases. University provides testing capabilities for formulation of antibiotic-bacteriophage combinations with optimal composition and stability against S. aureus and P. aeruginosa.
• Biotechnologický ústav AV ČRcoreStrategic or Co-development Partner · 1 January 2017Research collaboration for development and production of recombinant phage endolysins against Paenibacillus larvae (American Foulbrood in bees). Institute provides biotechnology expertise for cloning and identifying suitable phage endolysin candidates.
• VFU Brno, Ústav ekologie a chorob zvěře, ryb a včelminorStrategic or Co-development Partner · 1 January 2017Collaboration for preclinical and clinical testing of new phage preparations on laboratory models and bees in valid clinical studies. Veterinary Faculty provides in vivo testing capabilities and expertise.
• FAGOFARMA s.r.o.coreStrategic or Co-development Partner · 1 January 2015Collaboration on veterinary bacteriophage product development for treatment of bacterial diseases in fish, bees, and cattle mammary gland inflammation. FAGOFARMA serves as sales partner for LYZODOL consumer supplement through fagocare.cz e-commerce platform.
• Dyntec spol. s.r.o.coreStrategic or Co-development Partner · 1 January 2015Collaboration partner in development of new veterinary medicines for bee disease treatment based on bacteriophage endolysins. Dyntec provides pharmaceutical expertise in building semi-works facility for new drug development.

Scale indicators5 records

Recent moves6 records

Expansion highlights7 records

Broad incumbents

• Lonza Group: Global CDMO leader offering biologics manufacturing services including microbial fermentation. Comparable to MB Pharma's contract manufacturing services division, though at vastly larger scale and broader scope.
• AGC Biologics: Global CDMO providing microbial and mammalian cell-based biologics manufacturing. Directly competes with MB Pharma's CDMO services for pharmaceutical and biotechnology clients in Europe.

Regional players

• BioGaia: Swedish probiotic company developing bacterial lysate-based and probiotic dietary supplements. Comparable to MB Pharma's LYZODOL product in bacterial lysate/immune-support supplements category, though MB Pharma is regional Czech market.
• Generi Biotech: Czech molecular diagnostics and biotechnology company providing laboratory diagnostic and research services. Regional Czech peer with similar biotech profile, though focused on diagnostics rather than therapeutics.

Direct peers

• Eligo Bioscience: French biotech developing phage-based precision therapeutics using engineered/phage payloads. Comparable to MB Pharma in phage-based therapeutic approach and European operations, with similar clinical-stage focus on antibacterial applications.
• OM Pharma: Swiss pharmaceutical company specializing in bacterial lysate-based immunomodulators (Broncho-Vaxom, Uro-Vaxom). Closely comparable to MB Pharma's LYZODOL and bacterial lysate technology platform, with established commercial products in respiratory immune support.
• Intralytix: US-based company developing bacteriophage-based products for human therapeutic and food safety applications. Directly comparable to MB Pharma in phage technology platform and focus on human therapeutic applications.
• Adaptive Phage Therapeutics: US-based clinical-stage developer of bacteriophage-based therapeutics for antibiotic-resistant infections. Most directly comparable to MB Pharma's DUOFAG and TRIOFAG programs, both targeting complicated bacterial infections with phage-based therapies. Operates in same clinical-stage and product category.
• Locus Biosciences: Clinical-stage phage therapy company developing engineered phage products for antibiotic-resistant bacterial infections. Comparable to MB Pharma's pipeline focus on phage-based therapeutics and partnership-driven business model.

Emerging players

• PhagoMed (now part of BioNTech): Austrian phage therapy company focused on bacterial vaginosis and other applications, acquired by BioNTech. Was a direct peer to MB Pharma in European phage therapeutics development before acquisition.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/mbpharma
• LinkedInlinkedin.com/company/mbph
• Xx.com/mb_pharma

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MB Pharma